clinical trial · NCT07538583

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

$QNRX →·phase3·recruiting·n = 16

Netherton SyndromeQRX003

brief summary

This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.

started

Mar 19, 2026

primary completion

Jan 31, 2027

completion

Mar 31, 2027

last updated

Apr 21, 2026

official title

A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol